**Background of BMPR1A Antibody**
BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β superfamily. It plays a critical role in mediating signaling pathways initiated by bone morphogenetic proteins (BMPs), which regulate diverse cellular processes, including proliferation, differentiation, apoptosis, and tissue homeostasis. BMPR1A binds BMP ligands (e.g., BMP-2. BMP-4) and forms a complex with type II receptors, activating downstream SMAD (SMAD1/5/8) and non-SMAD pathways (e.g., MAPK, PI3K).
BMPR1A antibodies are essential tools for studying BMP signaling in developmental biology, cancer research, and regenerative medicine. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect BMPR1A expression, localization, and activation states. Dysregulation of BMPR1A is linked to diseases such as juvenile polyposis syndrome (germline mutations), colorectal cancer, and pulmonary arterial hypertension, making its detection crucial for mechanistic and diagnostic studies.
These antibodies are typically raised against specific epitopes (e.g., cytoplasmic or extracellular domains) in hosts like rabbits or mice. Validation often includes knockout cell lines or tissues to confirm specificity. Researchers prioritize antibodies with high affinity, minimal cross-reactivity, and compatibility with their experimental models (human, mouse, rat). Commercial BMPR1A antibodies are available in various formats (monoclonal/polyclonal), enabling tailored applications in basic and translational research.